Sistemic to Perform MicroRNA Screening for Redx Pharma | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Scottish firm Sistemic today announced a master service agreement to use its SistemRNA suite of drug development tools to accelerate Redx Pharma's preclinical development pipeline of more than 250 new drug candidates.

The agreement follows a project between the two companies in which Sistemic "added significant value" to a lead program of Redx while saving significant costs, Sistemic said.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?